FDA Accepts Roflumilast Foam NDA for the Treatment of Seborrheic Dermatitis

Press/Media

Period	15 Jun 2023

Media coverage

Title	FDA Accepts Roflumilast Foam NDA for the Treatment of Seborrheic Dermatitis
Media name/outlet	South Africa - Knowledia News
Country/Territory	South Africa
Date	15/06/23
URL	ct.moreover.com/?a=51056220818&p=1gw&v=1&x=6j8dAVeeYq53nYLbAQB5eQ
Persons	Peter Lio